SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-020558
Filing Date
2022-08-15
Accepted
2022-08-15 17:00:07
Documents
70
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20220630_10q.htm   iXBRL 10-Q 1397606
2 EXHIBIT 31.1 ex_410920.htm EX-31.1 8506
3 EXHIBIT 31.2 ex_410921.htm EX-31.2 8526
4 EXHIBIT 32.1 ex_410922.htm EX-32.1 4358
5 EXHIBIT 32.2 ex_410923.htm EX-32.2 4283
  Complete submission text file 0001437749-22-020558.txt   7046612

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20220630.xsd EX-101.SCH 59139
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20220630_cal.xml EX-101.CAL 39078
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220630_def.xml EX-101.DEF 469414
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220630_lab.xml EX-101.LAB 360253
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220630_pre.xml EX-101.PRE 490432
64 EXTRACTED XBRL INSTANCE DOCUMENT navb20220630_10q_htm.xml XML 1183892
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 221166474
SIC: 2835 In Vitro & In Vivo Diagnostic Substances